Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 2, 2012, Pages 624-629

  Abdollah, Firas ^a   Cozzarini, Cesare ^a   Suardi, Nazareno ^a   Gallina, Andrea ^a   Capitanio, Umberto ^a   Bianchi, Marco ^a   Tutolo, Manuela ^a   Salonia, Andrea ^a   La MacChia, Mariangela ^a   Di Muzio, Nadia ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a   Briganti, Alberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Extended pelvic lymph node dissection; Lymph node invasion; Prediction model; Prostate cancer; Roach formula

Indexed keywords

LYMPH NODE; PELVIC LYMPH NODES; PREDICTION MODEL; PROSTATE CANCERS; ROACH FORMULA;

BODY FLUIDS; DISEASES; DISSECTION; INFORMATION SERVICES; MATHEMATICAL MODELS; PATIENT MONITORING; UROLOGY;

PATIENT TREATMENT;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; CANCER PATIENT; HIGH RISK PATIENT; HUMAN; ILIAC ARTERY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OBTURATOR HERNIA; PELVIS LYMPH NODE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TERTIARY HEALTH CARE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CALIBRATION; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PELVIS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84861016544     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.06.2014     Document Type: Article

References (20)

1. M. Roach III, C. Marquez, and H.S. Yuo Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 28 1994 33 37 (Pubitemid 24012852)
2. M. Roach, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911 (Pubitemid 46606377)
3. C.A. Lawton, M. DeSilvio, and M. Roach III An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655 (Pubitemid 47418390)
4. A.W. Partin, J. Yoo, and H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114 (Pubitemid 23175983)
5. M.R. Cooperberg, J.W. Moul, and P.R. Carroll The changing face of prostate cancer J Clin Oncol 23 2005 8146 8151 (Pubitemid 46211547)
6. A. Gallina, F.K. Chun, and N. Suardi Comparison of stage migration patterns between Europe and the USA: An analysis of 11,350 men treated with radical prostatectomy for prostate cancer BJU Int 101 2008 1513 1518 (Pubitemid 351704026)
7. P.L. Nguyen, M.H. Chen, and K.E. Hoffman Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era Int J Radiat Oncol Biol Phys 74 2009 104 109
8. J.B. Yu, D.V. Makarov, and C. Gross A new formula for prostate cancer lymph node risk Int J Radiat Oncol Biol Phys 80 2011 69 75
9. F. Abdollah, M. Sun, and R. Thuret Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer Eur Urol 58 2010 882 892
10. A. Briganti, F.K. Chun, and A. Salonia Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy Urology 69 2007 147 151 (Pubitemid 46161677)
11. A. Heidenreich, Z. Varga, and R. Von Knobloch Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis J Urol 167 2002 1681 1686 (Pubitemid 34240702)
12. B.H. Bochner, D. Choi, and H.W. Herr Prospectively packaged lymph node dissections with radical cystectomy. Evaluation of node count variability and node mapping J Urol 172 2004 878 881
13. A. Mattei, F.G. Fuechsel, and N. Bhatta Dhar The template of the primary lymphatic landing sites of the prostate should be revisited: Results of a multimodality mapping study Eur Urol 53 2008 118 125 (Pubitemid 350166722)
14. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
15. A. Briganti, M.L. Blute, and J.H. Eastham Pelvic lymph node dissection in prostate cancer Eur Urol 55 2009 1251 1265
16. J. Mohler, R.R. Bahnson, and B. Boston NCCN clinical practice guidelines in oncology: Prostate cancer J Natl Compr Canc Netw 8 2010 162 200
17. Scosyrev E, Messing J, Noyes, et al. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: An overview. Urol Oncol doi: 10.1016/j.urolonc.2009.11.005
18. F.K. Chun, T. Steuber, and A. Erbersdobler Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology Eur Urol 49 2006 820 826
19. M. Graefen, H. Augustin, and P.I. Karakiewicz Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables Eur Urol 43 2003 6 10
20. A. Briganti, S.F. Shariat, and F.K. Chun Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin BJU Int 100 2007 528 532 (Pubitemid 47205464)